References of "De Tullio, Pascal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDetermination of Albendazole and Its Main Metabolites in Ovine Plasma by Liquid Chromatography with Dialysis as an Integrated Sample Preparation Technique
Chiap, Patrice ULg; Evrard, Brigitte ULg; Bimazubute, M. A. et al

in Journal of Chromatography. A (2000), 870(1-2), 121-34

Albendazole is a benzimidazole derivative with a broad-spectrum activity against human and animal helminth parasites. In order to determine the main pharmacokinetic parameters in sheep after oral and ... [more ▼]

Albendazole is a benzimidazole derivative with a broad-spectrum activity against human and animal helminth parasites. In order to determine the main pharmacokinetic parameters in sheep after oral and intravenous administration of a new formulation of albendazole (an aqueous solution), a fully automated method was developed for the determination of this drug and its main metabolites, albendazole sulfoxide (active metabolite) and sulfone in ovine plasma. This method involves dialysis as purification step, followed by enrichment of the dialysate on a precolumn and liquid chromatography (LC). All sample handling operations were executed automatically by means of an ASTED XL system. After conditioning of the trace enrichment column (TEC) packed with octadecyl silica with pH 6.0 phosphate buffer containing sodium azide, the plasma sample, in which a protein releasing reagent (1 M HCl) containing Triton X-100 was automatically added, was loaded in the donor channel and dialysed on a cellulose acetate membrane in the static-pulsed mode. The dialysis liquid consisted of pH 2.5 phosphate buffer. By rotation of a switching valve, the analytes were eluted from the TEC in the back-flush mode by the LC mobile phase and transferred to the analytical column, packed with octyl silica. The chromatographic separation was performed at 35 degrees C and the analytes were monitored photometrically at 295 nm. Due to the differences in hydrophobic character between albendazole and its metabolites, a gradient elution was applied. The mobile phase consisted of a mixture of acetonitrile and pH 6.0 phosphate buffer. The proportion of organic modifier was increased from 10.0 to 50.1% in 12.30 min, then from 50.1 to 66.9% in 1.70 min. First, the gradient conditions and the temperature were optimised for the LC separation using the DryLab software. Then, the influence of some parameters of the dialysis process on analyte recovery was investigated. Finally, the method developed was validated. The mean recoveries for albendazole and its metabolites were about 70 and 65%, respectively. The limits of quantification for albendazole and its metabolites were 10 and 7.5 ng/ml, respectively. [less ▲]

Detailed reference viewed: 30 (0 ULg)
Full Text
Peer Reviewed
See detailRecent advances in inducible cyclooxygenase (COX-2) inhibition
De Leval, X.; Delarge, J.; Somers, F. et al

in Current Medicinal Chemistry (2000), 7(10), 1041-1062

Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as ... [more ▼]

Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal anti-inflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs. [less ▲]

Detailed reference viewed: 18 (3 ULg)
Peer Reviewed
See detailEffect on the pancreatic endocrine system of 3-alkylamino-7-chloro-4H-1,2,4-benzothiadiazine 1,1-dioxides structurally related to diazoxide
Boverie, S.; Antoine, M.-H.; Becker, B. et al

in Pflügers Archiv : European Journal of Physiology (2000), 439

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detail7-Substituted alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as new analogues of diazoxide: effects on the insulin releasing process in vitro
Boverie, S.; Somers, F.; Ouedraogo, R. et al

in Fundamental & Clinical Pharmacology (2000), 14

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailTherapeutic and chemical developments of cholecystokinin receptor ligands
De Tullio, Pascal ULg; Delarge, J.; Pirotte, Bernard ULg

in Exp. Opin. Invest. Drugs (2000), 9

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailSynthesis and biological effects of new 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides on insulin-secreting cells
Somers, F.; De Tullio, Pascal ULg; Boverie, S. et al

in Pharmacy and Pharmacology Communications (2000), 6

Detailed reference viewed: 6 (0 ULg)
See detail1,2,4-Benzothiadiazine derivatives, their preparation and use
De Tullio, Pascal ULg; Nielsen, F. E.; Hansen, J. B. et al

Patent (1999)

Detailed reference viewed: 96 (4 ULg)
See detailPyrido 1,2,4-thiadiazine derivatives, their preparation and use
De Tullio, Pascal ULg; Boverie, S.; Somers, F. et al

Patent (1999)

Detailed reference viewed: 5 (0 ULg)